- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMX Aktie jetzt für 0€ handeln | |||||
| Di | BiomX Inc: BiomX Issues Statement Regarding Recent Common Stock Trading Activity | 4 | GlobeNewswire (USA) | ||
| Di | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | 226 | AFX News | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 14.01. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 29.12.25 | BiomX Inc: BiomX Announces $3.0 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 17.12.25 | BiomX collapses into court proceedings after clinical trial fails | 6 | CTech | ||
| 08.12.25 | BiomX Inc: BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review | 176 | GlobeNewswire (Europe) | Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in... ► Artikel lesen | |
| 08.12.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.11.25 | H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries | 10 | Investing.com | ||
| 28.11.25 | BiomX: H.C. Wainwright bestätigt Kaufempfehlung trotz FDA-Rückfragen zum Inhalator | 5 | Investing.com Deutsch | ||
| 26.11.25 | BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review | 8 | Benzinga.com | ||
| 26.11.25 | BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 | 1 | RTTNews | ||
| 25.11.25 | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis | 232 | GlobeNewswire (Europe) | The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used... ► Artikel lesen | |
| 25.11.25 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | BiomX to implement 1-for-19 reverse stock split on November 25 | 1 | Investing.com | ||
| 14.11.25 | BiomX announces 1-for-19 reverse stock split | 4 | Seeking Alpha | ||
| 14.11.25 | BiomX Inc. Announces 1-for-19 Reverse Stock Split | 195 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 12.11.25 | BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections | 2 | Seeking Alpha | ||
| 12.11.25 | BiomX GAAP EPS of $0.29 | 2 | Seeking Alpha |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 100,20 | +0,96 % | BioNTech Aktie: Goldman Sachs mit Ritterschlag! Hohes Kurspotential! | © Foto: Foto von Ricardo Cruz auf UnsplashTolle News für die Mainzer. Goldman Sachs stuft BioNTech höher ein und setzt ein neues Kursziel. Das ist mehr als nur eine technische Anpassung. Es ist ein... ► Artikel lesen | |
| AMGEN | 293,35 | +0,41 % | Amgen (AMGN): Ausbruch geglückt - Warum Trader jetzt die Marke von 345 USD genau im Auge behalten. | Perfekte Einstiegschance nach dem Pullback? Rückblick Amgen ist ein führendes Biotechnologieunternehmen und setzt stark auf Medikamente wie MariTide (Gewichtsverlust-Kandidat), das direkt mit den Produkten... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,280 | +0,79 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,429 | +9,72 % | Defence Therapeutics Inc.: Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics | Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,104 | -1,36 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| CARDIOL THERAPEUTICS | 0,810 | -1,82 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,330 | 0,00 % | RedHill Biopharma Ltd. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KYNTRA BIO | 7,050 | +0,71 % | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| ARMATA PHARMACEUTICALS | 5,400 | -0,92 % | Armata Pharmaceuticals, Inc. - 8-K, Current Report | ||
| VAXCYTE | 44,800 | -0,88 % | Vaxcyte, Inc.: Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine | VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 6,000 | -1,64 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | - Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity-... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead | NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,750 | +0,64 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome | First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102... ► Artikel lesen | |
| CG ONCOLOGY | 55,10 | +3,38 % | What Analysts Are Saying About CG Oncology Stock |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.